MX2022003855A - Formulaciones de fenilacetato de l-ornitina. - Google Patents
Formulaciones de fenilacetato de l-ornitina.Info
- Publication number
- MX2022003855A MX2022003855A MX2022003855A MX2022003855A MX2022003855A MX 2022003855 A MX2022003855 A MX 2022003855A MX 2022003855 A MX2022003855 A MX 2022003855A MX 2022003855 A MX2022003855 A MX 2022003855A MX 2022003855 A MX2022003855 A MX 2022003855A
- Authority
- MX
- Mexico
- Prior art keywords
- ornithine phenylacetate
- liver
- patients
- oral formulations
- formulations
- Prior art date
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010020575 Hyperammonaemia Diseases 0.000 abstract 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 208000030954 urea cycle disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y a métodos para preparar las mismas. Estas formulaciones orales ofrecen una ruta alternativa de administración diferente de la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tiene varias enfermedades y trastornos hepáticos crónicos y agudos, por ejemplo, falla hepática aguda, cirrosis hepática, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562150238P | 2015-04-20 | 2015-04-20 | |
US201562150676P | 2015-04-21 | 2015-04-21 | |
US201562211619P | 2015-08-28 | 2015-08-28 | |
US201562255300P | 2015-11-13 | 2015-11-13 | |
US201662276754P | 2016-01-08 | 2016-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003855A true MX2022003855A (es) | 2023-03-02 |
Family
ID=57144228
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013170A MX2017013170A (es) | 2015-04-20 | 2016-04-19 | Formulaciones de fenilacetato de l-ornitina. |
MX2022003855A MX2022003855A (es) | 2015-04-20 | 2017-10-12 | Formulaciones de fenilacetato de l-ornitina. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013170A MX2017013170A (es) | 2015-04-20 | 2016-04-19 | Formulaciones de fenilacetato de l-ornitina. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160338982A1 (es) |
EP (2) | EP3285756B1 (es) |
JP (2) | JP2018513171A (es) |
KR (1) | KR20180006904A (es) |
CN (2) | CN107708684A (es) |
AU (2) | AU2016252382A1 (es) |
CA (1) | CA2983146C (es) |
DK (1) | DK3285756T3 (es) |
ES (1) | ES2944311T3 (es) |
HK (1) | HK1251149A1 (es) |
MX (2) | MX2017013170A (es) |
RU (1) | RU2755904C2 (es) |
WO (1) | WO2016172112A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2537974T3 (es) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
WO2017083758A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulation of l-ornithine phenylacetate |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
KR20200024145A (ko) | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조방법 |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
ES2537974T3 (es) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
SG174982A1 (en) * | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
ES2517340T3 (es) * | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
WO2012048043A1 (en) | 2010-10-06 | 2012-04-12 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
-
2016
- 2016-04-19 US US15/133,087 patent/US20160338982A1/en not_active Abandoned
- 2016-04-19 CA CA2983146A patent/CA2983146C/en active Active
- 2016-04-19 AU AU2016252382A patent/AU2016252382A1/en not_active Abandoned
- 2016-04-19 WO PCT/US2016/028298 patent/WO2016172112A1/en active Application Filing
- 2016-04-19 EP EP16783692.3A patent/EP3285756B1/en active Active
- 2016-04-19 MX MX2017013170A patent/MX2017013170A/es unknown
- 2016-04-19 CN CN201680036045.1A patent/CN107708684A/zh active Pending
- 2016-04-19 CN CN202110931620.7A patent/CN113599350A/zh active Pending
- 2016-04-19 JP JP2017554815A patent/JP2018513171A/ja active Pending
- 2016-04-19 RU RU2017137643A patent/RU2755904C2/ru active
- 2016-04-19 EP EP23157390.8A patent/EP4205735A1/en not_active Withdrawn
- 2016-04-19 ES ES16783692T patent/ES2944311T3/es active Active
- 2016-04-19 KR KR1020177032260A patent/KR20180006904A/ko not_active Application Discontinuation
- 2016-04-19 DK DK16783692.3T patent/DK3285756T3/da active
-
2017
- 2017-10-12 MX MX2022003855A patent/MX2022003855A/es unknown
-
2018
- 2018-08-16 HK HK18110518.2A patent/HK1251149A1/zh unknown
-
2021
- 2021-02-05 AU AU2021200740A patent/AU2021200740A1/en active Pending
- 2021-12-22 US US17/559,453 patent/US20220184014A1/en not_active Abandoned
-
2022
- 2022-03-23 JP JP2022046762A patent/JP2022101549A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2983146C (en) | 2023-09-12 |
RU2017137643A3 (es) | 2019-09-17 |
AU2016252382A1 (en) | 2017-11-02 |
HK1251149A1 (zh) | 2019-01-25 |
EP3285756B1 (en) | 2023-02-22 |
WO2016172112A1 (en) | 2016-10-27 |
DK3285756T3 (da) | 2023-05-08 |
CA2983146A1 (en) | 2016-10-27 |
EP3285756A4 (en) | 2019-01-23 |
JP2018513171A (ja) | 2018-05-24 |
AU2021200740A1 (en) | 2021-03-04 |
US20220184014A1 (en) | 2022-06-16 |
CN107708684A (zh) | 2018-02-16 |
EP3285756A1 (en) | 2018-02-28 |
JP2022101549A (ja) | 2022-07-06 |
RU2017137643A (ru) | 2019-05-20 |
EP4205735A1 (en) | 2023-07-05 |
CN113599350A (zh) | 2021-11-05 |
MX2017013170A (es) | 2018-04-11 |
US20160338982A1 (en) | 2016-11-24 |
RU2755904C2 (ru) | 2021-09-22 |
KR20180006904A (ko) | 2018-01-19 |
ES2944311T3 (es) | 2023-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003855A (es) | Formulaciones de fenilacetato de l-ornitina. | |
MX2022001517A (es) | Formulaciones de fenilacetato de l-ornitina. | |
CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
MA42950A (fr) | Administration d'agents de potentialisation de cftr modifiés au deutérium | |
PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
MX2012011222A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. | |
PH12015502588A1 (en) | 4`-fluoro-2`-methyl substituted nucleoside derivatives | |
MX371093B (es) | Compuestos de microarn y metodos para modular al mir-122. | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
UY36586A (es) | Heterociclilmetiltienouracilos y uso de los mismos | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
UA116053C2 (uk) | Застосування похідних бензоімідазолу-проліну | |
BR112018000217A2 (pt) | sistemas de distribuição de nanopartículas aperfeiçoados | |
MX2018007871A (es) | Composiciones para el cuidado personal. | |
BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
MX2015014307A (es) | Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados. | |
EA201890477A1 (ru) | Инкапсулированная композиция финголимода | |
PH12018500895A1 (en) | Formulation of l-ornithine phenylacetate | |
BR112017006449A2 (pt) | concentrado alimentar gelificado, processo de preparo e uso do mesmo | |
MX2022004449A (es) | Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia. | |
BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
CL2020001559A1 (es) | Derivados glucosídicos de treprostinilo. | |
BR112017006438A2 (pt) | concentrado alimentar gelificado, processo para a preparação e uso do mesmo | |
MX2021001361A (es) | Composicion liquida de fibrinogeno humano. |